Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
April 27, 2009
- Majority of Major Drug Firms Increase Hiring of New Graduates in 2009
April 27, 2009
- Coefficients for Generics for DPC Hospitals May Be Introduced
April 27, 2009
- Yokohama Clinic Starts Cancer Therapy Using Dendritic Cells
April 27, 2009
- PMDA Creates New Office to Review Anticancer Drugs
April 27, 2009
- Asahi Kasei Licenses Flivas to Dong-A
April 27, 2009
- BUSINESS NEWS IN BRIEF
April 27, 2009
- Otsuka Aims at Further Growth Driven by Its Own Products in Oncology, CNS
April 27, 2009
- Drug Market in China to Reach US$50 Bil. in 2012
April 27, 2009
- Kowa, Apo Plus Station Creates "Career & Leaps" to Support Marketing of OTC Drugs
April 20, 2009
- Kissei's Urief Launched in the US
April 20, 2009
- Alpha MOS Sets Up Japanese Subsidiary
April 20, 2009
- Daiichi Sankyo, Eli Lilly Launch Prasugrel in UK
April 20, 2009
- Takara Bio Obtains License from Kyoto Univ.
April 20, 2009
- Eli Lilly Licenses Cialis to Nippon Shinyaku
April 20, 2009
- GE, Intel Ally in Home Health Technologies
April 20, 2009
- Otsuka, BMS Extend Agreement on Abilify, Embark on Global Oncology Collaboration
April 20, 2009
- Olympus Releases Biliary Stent Jointly with Medinol
April 20, 2009
- Pfizer Aims to Become Market Leader for Macrolides with Zithromac SR
April 20, 2009
- AMDD Inaugurated with Dr H. Wang as President
April 20, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…